Nanoparticle Drug Delivery for Neurodegeneration

Migration, Crosslink

📖

Nanoparticle Drug Delivery for Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-nanoparticle-drug-deli

📖 Wiki Page

therapeutic2880 wordssynced 2026-04-02

Nanoparticle Drug Delivery for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nanoparticle Drug Delivery for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">BBB crossing</td>
<td>Significantly improved CNS delivery compared to free drugs</td>
</tr>
<tr>
<td class="label">Sustained release</td>
<td>Reduced dosing frequency; maintains therapeutic drug levels over extended periods</td>
</tr>
<tr>
<td class="label">Targeted delivery</td>
<td>Reduced off-target systemic effects</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>Multiple drugs can be co-loaded in a single nanoparticle</td>
</tr>
<tr>
<td class="label">Theranostics</td>
<td>Integrated diagnostic and therapeutic functions</td>
</tr>
<tr>
<td class="label">Versatility</td>
<td>Can deliver small molecules, proteins, nucleic acids, and cells</td>
</tr>
<tr>
<td class="label">Protection</td>
<td>Nanoparticles protect cargo from enzymatic degradation</td>
</tr>
<tr>
<td class="label">Dose reduction</td>
<td>More efficient delivery may allow lower doses</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Immunogenicity</td>
<td>Some nanoparticles (especially viral-based) trigger immune responses; PEG antibodies can reduce efficacy</td>
</tr>
<tr>

...

Nanoparticle Drug Delivery for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nanoparticle Drug Delivery for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">BBB crossing</td>
<td>Significantly improved CNS delivery compared to free drugs</td>
</tr>
<tr>
<td class="label">Sustained release</td>
<td>Reduced dosing frequency; maintains therapeutic drug levels over extended periods</td>
</tr>
<tr>
<td class="label">Targeted delivery</td>
<td>Reduced off-target systemic effects</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>Multiple drugs can be co-loaded in a single nanoparticle</td>
</tr>
<tr>
<td class="label">Theranostics</td>
<td>Integrated diagnostic and therapeutic functions</td>
</tr>
<tr>
<td class="label">Versatility</td>
<td>Can deliver small molecules, proteins, nucleic acids, and cells</td>
</tr>
<tr>
<td class="label">Protection</td>
<td>Nanoparticles protect cargo from enzymatic degradation</td>
</tr>
<tr>
<td class="label">Dose reduction</td>
<td>More efficient delivery may allow lower doses</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Immunogenicity</td>
<td>Some nanoparticles (especially viral-based) trigger immune responses; PEG antibodies can reduce efficacy</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Scalable, reproducible manufacturing remains difficult for complex nanoparticles</td>
</tr>
<tr>
<td class="label">Regulatory</td>
<td>Novel formulations require extensive characterization and safety testing</td>
</tr>
<tr>
<td class="label">Biodistribution</td>
<td>Accumulation in liver, spleen, and RES organs reduces brain delivery efficiency</td>
</tr>
<tr>
<td class="label">BBB heterogeneity</td>
<td>BBB integrity varies between diseases and across disease stages</td>
</tr>
<tr>
<td class="label">Long-term toxicity</td>
<td>Chronic exposure effects are not well characterized for most nanoparticle platforms</td>
</tr>
<tr>
<td class="label">Targeting specificity</td>
<td>Achieving truly selective targeting vs. general increased brain penetration</td>
</tr>
<tr>
<td class="label">Brain pharmacokinetics</td>
<td>Limited understanding of how nanoparticles distribute within the brain after crossing the BBB</td>
</tr>
</table>

Nanoparticle drug delivery systems represent one of the most promising strategies for overcoming the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) to treat [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and other neurodegenerative diseases. The BBB, formed by tightly joined brain endothelial cells surrounded by pericytes and astrocyte end-feet, excludes over 98% of small-molecule drugs and virtually all large-molecule therapeutics from the central nervous system. Nanoparticle platforms offer a versatile toolkit for transporting therapeutic cargo — including small molecules, proteins, nucleic acids, and cell-based therapies — across this formidable barrier[@saraiva2016; @masserini2013; @ariasalpizar2020].

The field has matured substantially over the past decade, with multiple nanoparticle platforms now showing promising results in preclinical models and early clinical trials. Key advances include the development of targeted nanoparticles functionalized with receptor-specific ligands, the engineering of stimuli-responsive release systems, and the emergence of messenger RNA (mRNA) delivery platforms that leverage the success of COVID-19 vaccines. The integration of diagnostic and therapeutic functions (theranostics) within single nanoparticle systems represents another frontier with significant clinical potential[@tiji2024; @silberberg2023; @chen2023].

Blood-Brain Barrier Biology and Nanoparticle Transport

The Blood-Brain Barrier

The BBB is a dynamic interface that regulates the passage of molecules between the blood and the brain. Its key components include:

Brain microvascular endothelial cells (BMECs): Form the physical barrier through tight junctions (claudins, occludin, ZO-1)
Basement membrane: A 50–100 nm extracellular matrix layer separating endothelial cells from pericytes and astrocytes
Pericytes: Provide structural support and regulate capillary tone and immune cell trafficking
Astrocyte end-feet: Cover 99% of capillary surface; release factors that maintain BBB integrity

Transport across the BBB occurs through several mechanisms:

Transcellular diffusion: Lipophilic molecules <400 Da can passively diffuse through endothelial membranes
Carrier-mediated transport (CMT): Glucose (GLUT1), amino acids, other nutrients use specific transporters
Receptor-mediated transcytosis (RMT): Large molecules (insulin, transferrin) bind surface receptors, triggering internalization
Adsorptive-mediated transcytosis (AMT): Cationic molecules bind negatively charged membrane surfaces

Nanoparticles exploit primarily RMT and, to a lesser extent, AMT pathways for brain delivery[@ariasalpizar2020].

Nanoparticle Transport Mechanisms

Nanoparticles achieve brain delivery through several key mechanisms:

Size-dependent extravasation: Nanoparticles smaller than 200 nm can, under certain conditions, cross the BBB. The optimal size range for CNS penetration is 10–100 nm; particles above 200 nm are largely excluded.

Surface charge: Neutral and slightly negative surfaces (zeta potential near 0 mV) show better brain penetration than strongly positive surfaces, which are rapidly cleared by the reticuloendothelial system (RES). Cationic surfaces enhance AMT but also increase RES clearance.

Surface modification: PEGylation (coating with polyethylene glycol) reduces opsonization and RES clearance, extending circulation time. Targeted nanoparticles display specific ligands (transferrin, lactoferrin, peptides) on their surface for receptor-mediated delivery.

Modulating tight junctions: Some nanoparticles (e.g., certain surface-functionalized dendrimers) can transiently open tight junctions to allow paracellular transport.

Nanoparticle Platforms

Lipid-Based Nanoparticles

Lipid-based nanoparticles (LNPs) are the most clinically advanced CNS delivery platform, with mRNA-LNP technology validated by COVID-19 vaccines[@suh2023; @patel2023]:

Liposomes: Spherical vesicles (50–200 nm) with a phospholipid bilayer surrounding an aqueous core. The first clinically approved nanoparticle system. For brain delivery, surface modification with polysorbate 80 (Tween 80) or transferrin receptor-targeting ligands enhances BBB penetration[@re2019].

Solid lipid nanoparticles (SLNs): Solid lipid core (triglycerides, waxes) stabilized by surfactants. Advantages include controlled drug release, physical stability, and scalable manufacturing. SLNs loaded with curcumin, resveratrol, and other neuroprotective compounds have shown efficacy in AD and PD models[@tiji2024].

Lipid nanoparticles (LNPs): The delivery vehicle for mRNA vaccines. LNPs for CNS delivery use ionizable cationic lipids that neutralize at physiological pH (reducing toxicity) and become positively charged in acidic endosomes (enabling cargo release). Brain-penetrant LNPs are actively being developed for mRNA therapeutics in neurodegenerative diseases[@suh2023; @lin2024].

Nano-emulsions: Oil-in-water emulsions (100–500 nm) containing drug dissolved in the oil phase. NanoBEO (a coenzyme Q10 nano-emulsion) has been evaluated for behavioral symptoms of dementia[@gupta2024]. Phytochemical nano-emulsions (curcumin, resveratrol) show improved brain bioavailability compared to free drug[@jain2022].

Polymeric Nanoparticles

Polymer-based platforms offer precise control over drug release kinetics and surface functionalization[@pine2020; @chen2023]:

PLGA nanoparticles: Poly(lactic-co-glycolic acid) particles (100–300 nm) are FDA-approved for drug delivery. Their biodegradability, tunable degradation rate, and biocompatibility make them ideal for sustained CNS drug release. PLGA nanoparticles loaded with rivastigmine, donepezil, and natural neuroprotectants have shown promise in AD models.

Polycaprolactone (PCL) nanoparticles: Slower degradation than PLGA, enabling ultra-long drug release (months) for chronic neurodegenerative disease treatment.

Dendrimers: Highly branched, monodisperse polymers (2–10 nm) with a central core, branching generations, and surface functional groups. Polyamidoamine (PAMAM) dendrimers functionalized with targeting ligands (e.g., lactoferrin) have shown excellent brain penetration[@zhang2022]. Dendrimer-based anti-inflammatory agents reduce neuroinflammation in AD and PD models.

Polyplexes: Polymer-based vectors for nucleic acid delivery (siRNA, ASO, plasmid DNA). Cationic polymers (PEI, PLL) condense nucleic acids into nanoparticles; PEGylation reduces toxicity. Polyplexes functionalized with BBB-targeting ligands deliver siRNA to microglia and neurons[@khafagia2023; @lin2024].

Inorganic Nanoparticles

Inorganic materials provide unique functionalities for imaging, photothermal therapy, and magnetic targeting[@bharadwaj2020; @aggarwal2023]:

Gold nanoparticles (AuNPs): Excellent biocompatibility and easy surface functionalization. Applications include:

Photothermal therapy: Near-infrared laser activates AuNPs, generating localized heat to ablate amyloid plaques or tumor cells
Drug delivery: AuNPs can be loaded with drugs and targeted to specific brain regions
Imaging: Computed tomography (CT) and photoacoustic imaging contrast agents

Magnetic nanoparticles (Fe3O4): Superparamagnetic iron oxide nanoparticles (SPIONs) enable:

MRI contrast enhancement for diagnostic imaging
Magnetic targeting: An external magnetic field guides particles to specific brain regions
Magnetic hyperthermia: Alternating magnetic fields cause local heating for therapeutic purposes
Cell tracking: Labeling transplanted stem cells for in vivo monitoring

Silica nanoparticles: Mesoporous silica nanoparticles (MSNs) offer high drug loading capacity, controlled release, and excellent biocompatibility. MSNs can be gated with stimuli-responsive coatings for triggered drug release.

Quantum dots: Fluorescent semiconductor nanocrystals for in vivo imaging and real-time tracking of drug delivery. Brain-targeting versions are under development.

Biological Nanoparticles

Biological materials offer inherent biocompatibility and targeting capabilities[@taylor2021; @hernandez2022]:

Exosomes: Natural extracellular vesicles (30–150 nm) released by all cells. Exosomes carry proteins, lipids, and nucleic acids and can cross the BBB. Patient-derived exosomes (e.g., from mesenchymal stem cells) are being explored for neurodegenerative disease therapy, showing anti-inflammatory and neuroprotective effects. Engineered exosomes displaying targeting ligands offer enhanced brain specificity.

Cell membrane-coated nanoparticles: Nanoparticles coated with whole cell membranes from specific cell types (e.g., macrophages, microglia) inherit the homing properties of those cells. This approach has been used to target inflammatory sites in the brain and to overcome RES clearance.

Virus-like particles (VLPs): Non-replicating viral capsids that retain the natural targeting machinery of viruses. VLPs can be engineered to display CNS-targeting ligands and loaded with therapeutic cargo.

Lipoprotein-inspired nanoparticles: Synthetic high-density lipoprotein (HDL)-mimicking nanoparticles that exploit the BBB's apoE receptor pathway, which naturally delivers cholesterol to the brain.

Targeting Strategies

Passive Targeting

Enhanced Permeability and Retention (EPR) effect: In neuroinflammation, the BBB becomes more permeable, allowing nanoparticle accumulation at disease sites. The EPR effect is more pronounced in brain tumors than in neurodegenerative diseases but contributes to targeting at sites of active neuroinflammation.

Size-dependent BBB penetration: Nanoparticles in the 10–100 nm range can penetrate the BBB through transcytosis pathways. Smaller particles (5–10 nm) may diffuse through the endothelial basement membrane more readily, while larger particles (>200 nm) are largely excluded.

Circulation time optimization: Long-circulating nanoparticles (via PEGylation or other stealth coatings) have more opportunities to interact with the BBB and undergo transcytosis.

Active Targeting

Active targeting involves functionalizing nanoparticles with ligands that bind to specific receptors on the BBB or within the brain parenchyma[@ariasalpizar2020; @tiji2024]:

Transferrin receptor (TfR) targeting: The TfR is highly expressed on brain endothelial cells and is a well-validated target for BBB transcytosis. Nanoparticles displaying transferrin, anti-TfR antibodies (OX26, 8D3), or TfR-binding peptides show significantly enhanced brain delivery.

Lactoferrin receptor targeting: Lactoferrin (Lf) is a natural iron-binding protein that crosses the BBB via receptor-mediated transport. Lf-decorated nanoparticles show enhanced brain uptake compared to non-targeted controls.

Insulin receptor targeting: The insulin receptor mediates transport of insulin across the BBB. Insulin-decorated nanoparticles exploit this pathway for CNS delivery.

Low-density lipoprotein receptor (LDLR) family: Nanoparticles functionalized with apoE or LDLR-binding peptides use the same pathway as endogenous lipoproteins.

Nicotinic acetylcholine receptor (nAChR) targeting: Angiopep-2, a peptide that binds to LRP1 and nAChR, has been extensively used to functionalize nanoparticles for brain targeting. ANG1005 (ANG1005paclitaxel) reached phase II clinical trials for brain metastases.

CD98 targeting: The CD98 heavy chain (4F2hc) is overexpressed on brain endothelial cells; 4F2hc-binding peptides enable BBB transcytosis.

Tumor necrosis factor receptor (TNFR) targeting: TNF-α-decorated nanoparticles target inflamed brain endothelium.

Cell-specific targeting beyond the BBB: Once inside the brain, nanoparticles can be further functionalized to target specific cell types:

Microglia targeting: CX3CR1 ligand (tremelip) functionalization targets microglia; mannose receptor targeting also shows microglial specificity
Neuron targeting: Tetanus toxin fragment (TTH) or rabies virus-derived peptides
Astrocyte targeting: Specific receptor-ligand pairs under development

Physical Targeting Methods

Magnetic targeting: External magnets applied to the skull direct magnetic nanoparticles to specific brain regions. This approach is particularly useful for localizing particles near tumors or focal lesions[@bharadwaj2020].

Focused ultrasound (FUS): Low-frequency FUS combined with systemically administered microbubbles transiently opens the BBB, allowing nanoparticles to enter. This technique enables spatially precise delivery to targeted brain regions.

Intranasal delivery: Bypassing the BBB entirely through nasal administration, with nanoparticles designed for optimal transport along olfactory and trigeminal nerve pathways to the brain.

Applications in Neurodegenerative Diseases

Alzheimer's Disease

Nanoparticle platforms address multiple AD pathological targets[@patel2023; @chen2023; @jain2022; @tiji2024; @khafagia2023]:

Amyloid-beta targeting:

Aβ antibodies loaded in polymeric nanoparticles with TfR targeting
Metal-chelating nanoparticles (e.g., clioquinol-loaded liposomes) to reduce metal-catalyzed Aβ aggregation
siRNA delivery against BACE1 using targeted lipid nanoparticles
Nano-formulations of Aβ-binding natural compounds (curcumin, resveratrol, epigallocatechin gallate)

Tau pathology:

Tau-targeted siRNA delivery to neurons
Nano-formulated microtubule-stabilizing agents
Anti-phospho-tau antibody delivery across the BBB

Neuroinflammation:

Anti-PU.1 siRNA in lipid nanoparticles reduces microglial activation and neuroinflammation[@khafagia2023]
Nano-dexamethasone formulations for anti-inflammatory effects
Curcumin and other natural anti-inflammatory compounds in nano-emulsions

Neuron保护:

Nano-delivery of neurotrophic factors (BDNF, NGF) to neurons
Mitochondrial-protective agent delivery (CoQ10 nano-formulations)

Diagnosis and imaging:

MRI contrast agents using SPIONs targeted to amyloid plaques
Quantum dot-based fluorescent imaging of Aβ aggregates
Theranostic nanoparticles combining diagnostic imaging with therapeutic delivery

Parkinson's Disease

Nanoparticle systems for PD focus on dopaminergic neuron protection, α-synuclein targeting, and symptom management[@mendez2024; @tiji2024]:

α-Synuclein targeting:

siRNA against α-synuclein using targeted nanoparticles
Nano-formulated aggregation inhibitors (e.g., EGCG nano-emulsions)
Antibody delivery across the BBB using lipid nanoparticles

Neuroprotection:

Brain-targeted nano-delivery of resveratrol for neuroprotective effects[@mendez2024]
Nano-formulated dopamine agonists (rotigotine nanoparticles)
Mitochondrial protective agents (CoQ10, MitoQ nano-formulations)

Anti-inflammatory:

Targeted delivery of anti-inflammatory compounds to microglia
Nano-curcumin for reducing neuroinflammation in PD

Gene therapy delivery:

AAV nano-formulations with enhanced brain penetration
Non-viral gene delivery systems for neurotrophic factor expression

Amyotrophic Lateral Sclerosis

ALS presents unique challenges for nanoparticle delivery due to the need to target motor [neurons](/entities/motor-neurons) throughout the CNS[@tiji2024; @silberberg2023]:

Gene silencing:

SOD1 or C9orf72 siRNA delivery using targeted lipid nanoparticles
ASO delivery for intron retention targeting

Neuroprotection:

Nano-formulated neurotrophic factors (GDNF, BDNF)
Anti-inflammatory nano-therapeutics targeting motor neuron microenvironment

Challenges: Motor neurons are particularly difficult to target with nanoparticles. The motor neuron somas in the spinal cord and brainstem are separated from the BBB by additional diffusion barriers (the spinal cord has a more restrictive blood-spinal cord barrier). Engineering nanoparticles that can reach these deep CNS structures remains a significant challenge.

Huntington's Disease

Nanoparticle strategies for [Huntington's disease](/diseases/huntingtons) focus on [huntingtin](/proteins/htt-protein) gene silencing and neuroprotection[@silberberg2023; @tiji2024]:

HTT siRNA delivery: Targeted lipid nanoparticles for allele-selective HTT knockdown
Anti-inflammatory nano-therapeutics: Targeting the inflammatory component of HD
Neurotrophic factor delivery: Supporting striatal neuron survival

Multiple Sclerosis

Nanoparticle delivery for [multiple sclerosis](/diseases/multiple-sclerosis) targets both immunomodulation and neuroprotection[@torresortega2022; @khafagia2023]:

Immune cell targeting: Nanoparticles designed to deliver immunomodulatory drugs to autoreactive T cells and microglia
Myelin repair: Nano-formulations of myelin-promoting factors
Blood-spinal cord barrier: Targeting considerations for spinal cord lesions

Clinical Considerations

Advantages of Nanoparticle Delivery

Challenges and Limitations

Safety Considerations

Acute toxicity: Some nanoparticle materials (e.g., high-dose cationic polymers, certain metals) cause direct tissue damage. Comprehensive safety profiling is required for each platform.

Neuroinflammation: Some nanoparticles (especially certain inorganic materials) can paradoxically induce neuroinflammation, undermining therapeutic benefit.

Long-term clearance: The fate of nanoparticles after drug release is not well characterized. Some materials (gold, silica) may accumulate with repeated dosing.

Impact on normal brain function: Chronic modulation of BBB transport mechanisms could disrupt normal CNS homeostasis.

Future Directions and Emerging Technologies

Next-Generation Platforms

mRNA delivery to the CNS: The success of mRNA-LNP vaccines opens a path for mRNA therapeutics in neurodegeneration. Potential applications include[@suh2023]:

mRNA encoding neurotrophic factors
mRNA for gene editing (base editing, prime editing) in neurons
mRNA for disease-modifying protein replacement

Gene editing delivery: CRISPR-Cas systems delivered via lipid nanoparticles for correcting dominant-negative mutations in AD, PD, and ALS[@lin2024].

Cell-specific targeting advances: Nanoparticles functionalized with cell-type-specific markers enable targeted delivery to microglia, astrocytes, or specific neuronal subpopulations.

Stimuli-responsive systems: pH-sensitive, enzyme-sensitive, or externally triggered (magnetic, ultrasonic) release systems for on-demand drug delivery.

Multifunctional theranostics: Integrated nanoparticles combining:

Disease-modifying drug delivery
Real-time imaging for treatment monitoring
Reporter genes for tracking nanoparticle distribution
Theranostic agents that visualize pathology (e.g., amyloid PET tracers) while delivering therapy

Personalized nanomedicine: Patient-derived exosomes or engineered cells for personalized neurodegenerative disease therapy.

Clinical translation pathways: Key focus areas for translating nanoparticle platforms to the clinic:

GMP manufacturing scale-up
BBB penetration validation in humanized models
Biomarker-driven patient selection
Combination therapy approaches

Mermaid Diagram: Nanoparticle CNS Delivery Strategies

Mermaid diagram (expand to render)

External Links

[NIH Nanoparticle Delivery Program](https://www.ninds.nih.gov/)
[Nature Nanotechnology - Brain Delivery](https://www.nature.com/nnano/)
[ClinicalTrials.gov - Nanoparticle Neurodegeneration](https://clinicaltrials.gov/ct2/results?cond=neurodegenerative+disease&term=nanoparticle)
[FDA Nanotechnology Guidance](https://www.fda.gov/regulatory-information/fda-regulation-nanotechnology)

References

[Saraiva C, et al., Nanoparticle-mediated brain drug delivery (2016)](https://pubmed.ncbi.nlm.nih.gov/27208862/)

[Masserini M, Nanoparticles for brain drug delivery (2013)](https://pubmed.ncbi.nlm.nih.gov/24083003/)

[Arias-Alpizar G, et al., BBB crossing with targeted nanoparticles (2020)](https://pubmed.ncbi.nlm.nih.gov/31926967/)

[Re F, et al., Liposomal nanocarriers for neurodegenerative disease therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31116188/)

[Pine R, et al., Polymeric nanoparticles for CNS drug delivery (2020)](https://pubmed.ncbi.nlm.nih.gov/31970564/)

[Patel P, et al., Lipid nanoparticles for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/39930497/)

[Chen X, et al., Multifunctional nanocarriers for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37966683/)

[Jain AK, et al., Nano-emulsions of phyto-constituents for neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/38676489/)

[Tiji S, et al., Neuronanomedicine: nanoparticle systems for AD and PD (2024)](https://pubmed.ncbi.nlm.nih.gov/37967664/)

[Khafagia ES, et al., Lipid-nanoparticle-mediated delivery of anti-PU.1 siRNA (2023)](https://pubmed.ncbi.nlm.nih.gov/38018280/)

[Silberberg L, et al., Nanomedicine platforms for BBB bypass (2023)](https://pubmed.ncbi.nlm.nih.gov/39638950/)

[Bharadwaj S, et al., Multifunctional magnetic nanoparticles (2020)](https://pubmed.ncbi.nlm.nih.gov/21258634/)

[Aggarwal D, et al., Gold nanoparticles for imaging and photothermal therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37547289/)

[Mendez A, et al., Brain-targeted nano-drug-delivery for resveratrol in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38032385/)

[Taylor M, et al., Exosomes as natural nanocarriers for CNS drug delivery (2021)](https://pubmed.ncbi.nlm.nih.gov/34021060/)

[Hernandez A, et al., Cell membrane-coated nanoparticles for brain targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/35688521/)

[Suh H, et al., mRNA delivery across the blood-brain barrier using LNPs (2023)](https://pubmed.ncbi.nlm.nih.gov/37434321/)

[Lin T, et al., siRNA delivery to microglia using targeted LNPs (2024)](https://pubmed.ncbi.nlm.nih.gov/38986812/)

[Zhang L, et al., Dendrimers for brain delivery of anti-inflammatory agents (2022)](https://pubmed.ncbi.nlm.nih.gov/34974371/)

[Wang R, et al., Inertial focusing-based microfluidic preparation of brain-targeted NPs (2024)](https://pubmed.ncbi.nlm.nih.gov/38782193/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-nanoparticle-drug-delivery-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-nanoparticle-drug-delivery-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-cab1f10116c9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-nanoparticle-drug-delivery-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

559

Outgoing

733

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Nanoparticle Drug Delivery for Neurodegeneration

Nanoparticle Drug Delivery for Neurodegeneration

Overview

Nanoparticle Drug Delivery for Neurodegeneration

Overview

Blood-Brain Barrier Biology and Nanoparticle Transport

The Blood-Brain Barrier

Nanoparticle Transport Mechanisms

Nanoparticle Platforms

Lipid-Based Nanoparticles

Polymeric Nanoparticles

Inorganic Nanoparticles

Biological Nanoparticles

Targeting Strategies

Passive Targeting

Active Targeting

Physical Targeting Methods

Applications in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Multiple Sclerosis

Clinical Considerations

Advantages of Nanoparticle Delivery

Challenges and Limitations

Safety Considerations

Future Directions and Emerging Technologies

Next-Generation Platforms

Mermaid Diagram: Nanoparticle CNS Delivery Strategies

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Nanoparticle Drug Delivery for Neurodegeneration

Nanoparticle Drug Delivery for Neurodegeneration

Overview

Nanoparticle Drug Delivery for Neurodegeneration

Overview

Blood-Brain Barrier Biology and Nanoparticle Transport

The Blood-Brain Barrier

Nanoparticle Transport Mechanisms

Nanoparticle Platforms

Lipid-Based Nanoparticles

Polymeric Nanoparticles

Inorganic Nanoparticles

Biological Nanoparticles

Targeting Strategies

Passive Targeting

Active Targeting

Physical Targeting Methods

Applications in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Multiple Sclerosis

Clinical Considerations

Advantages of Nanoparticle Delivery

Challenges and Limitations

Safety Considerations

Future Directions and Emerging Technologies

Next-Generation Platforms

Mermaid Diagram: Nanoparticle CNS Delivery Strategies

See Also

External Links

References

Related Hypotheses

💬 Discussion